EGFR and neoplasm: The anti-EGFR-modified SPIONs developed by Shahbazi-Gahrouei et al. [119] demonstrated excellent tumor accumulation characteristics in lung cancer models, but the targeting efficiency observed in preclinical studies is often difficult to replicate in humans.